

**MHRA**  
10 South Colonnade  
Canary Wharf  
London  
E14 4PU  
United Kingdom

[gov.uk/mhra](http://gov.uk/mhra)

## Decision Cover Letter

### Decision of the licensing authority to:

accept change(s) to the agreed paediatric investigation plan (MHRA-100140-PIP01-21) and to the deferral.

MHRA-100140-PIP01-21-M01

### Scope of the Application

#### Active Substance(s)

BENRALIZUMAB

#### Condition(s)

Treatment of Hypereosinophilic Syndrome (HES)

#### Pharmaceutical Form(s)

Solution for injection; Solution for injection/infusion

#### Route(s) of Administration

SUBCUTANEOUS USE

#### Name / Corporate name of the PIP applicant

ASTRAZENECA UK LIMITED

#### Basis for the Decision

Pursuant to the Human Medicines Regulations 2012, ASTRAZENECA UK LIMITED submitted to the licensing authority on 08/10/2025 17:12 BST an application for a Modification

The procedure started on 04/11/2025 17:23 GMT

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

to accept change(s) to the agreed paediatric investigation plan and to the deferral.

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

**MHRA**  
10 South Colonnade  
Canary Wharf  
London  
E14 4PU  
United Kingdom

[gov.uk/mhra](http://gov.uk/mhra)

## Final Decision Letter

MHRA-100140-PIP01-21-M01

Of 28/11/2025 06:56 GMT

On the adopted decision for BENRALIZUMAB (MHRA-100140-PIP01-21-M01) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Agreement on modification of a paediatric investigation plan (including modification of a waiver or deferral included in that paediatric investigation plan).

This decision applies to a Modification for BENRALIZUMAB, Solution for injection; Solution for injection/infusion , SUBCUTANEOUS USE .

This decision is addressed to ASTRAZENECA UK LIMITED, 1 Francis Crick Avenue, Cambridge, UNITED KINGDOM, CB2 0AA

## ANNEX I

### 1. Waiver

#### 1.1 Condition:

Treatment of Hypereosinophilic Syndrome (HES). The waiver applies / applied to: Paediatric Subset(s): The paediatric population from birth to less than 6 years of age. Pharmaceutical form(s): Solution for injection Solution for injection/infusion Route(s) of administration: SUBCUTANEOUS USE Reason for granting waiver: on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies(s) are not feasible.

### 2. Paediatric Investigation Plan:

#### 2.1 Condition(s):

Treatment of Hypereosinophilic Syndrome (HES).

**2.2 Indication(s) targeted by the PIP:**

Treatment of Hypereosinophilic Syndrome (HES).

**2.3 Subset(s) of the paediatric population concerned by the paediatric development:**

The paediatric population from 6 years to less than 18 years of age.

**2.4 Pharmaceutical Form(s):**

Solution for injection Solution for injection/infusion

**2.5 Studies:**

Study Type	Number of Studies	Study Description
<b>Quality Measures</b>	0	Not applicable.
<b>Non-Clinical Studies</b>	0	Not applicable.
<b>Clinical Studies</b>	2	Study 1 (NATRON; D3254C00001) Randomised, placebo-controlled, double-blind, parallel-group, multicentre, study to evaluate the efficacy and safety of benralizumab in adolescents from 12 years to less than 18 years of age (and adults) with symptomatic active HES who were determined as responsive to oral corticosteroid treatment. Study 2 (CLIPS) Open-label study to evaluate the long-term safety, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of benralizumab in children aged from 6 years to less than 12 years of age with a documented diagnosis of HES (in addition to children with other eosinophilic diseases).
<b>Extrapolation, Modeling &amp; Simulation Studies</b>	2	Study 3 Modelling and simulation study to evaluate the use of the product in children from 6 years to less than 12 years of age with HES (and other eosinophilic diseases). Study 4 Partial extrapolation study based on population pharmacokinetics (PK) and population PK/pharmacodynamics

		(PD) models and clinical data from adults/ adolescents with HES (source population) to children with HES aged 6 years to < 12 years (target population).
<b>Other Studies</b>	0	Not applicable.
<b>Other Measures</b>	0	Not applicable.

### 3. Follow-up, completion and deferral of a PIP:

<b>Concerns on potential long term safety and efficacy issues in relation to paediatric use:</b>	No
<b>Date of completion of the paediatric investigation plan:</b>	31/01/2030
<b>Deferral of one or more studies contained in the paediatric investigation plan:</b>	Yes